39188-62-0

Usage

Uses

Used in Pharmaceutical Industry:
4-BENZYLOXYPHENYLACETYL CHLORIDE is used as a chemical intermediate for the synthesis of various drugs and pharmaceuticals. Its unique molecular structure allows for the introduction of the benzoyl group into other molecules, facilitating the development of new therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 4-BENZYLOXYPHENYLACETYL CHLORIDE is employed as a reagent for introducing the benzoyl group into other molecules. This capability is crucial for the creation of new organic compounds with specific properties and applications.
Used in Research and Development:
4-BENZYLOXYPHENYLACETYL CHLORIDE is utilized in research and development settings to explore its potential applications and to understand its chemical properties and reactivity. This knowledge can contribute to the advancement of chemical science and the discovery of novel compounds with practical uses.

Upstream product

• 6547-53-1 2-[4-(benzyloxy)benzyl]acetic acid 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 156-38-7 4-hydroxyphenylacetate 
• 838-96-0 2-[4-(benzyloxy)phenyl]acetonitrile 

Downstream Products

• 132257-11-5 (4-benzyloxy-phenyl)-acetic acid-(4-benzyloxy-3-methoxy-phenethylamide) 
• 54170-03-5 (4-benzyloxy-phenyl)-acetic acid-(4-hydroxy-3-methoxy-phenethylamide) 
• 84199-13-3 4-benzyloxybenzene-acetamide 
• 858817-08-0 (4-benzyloxy-phenyl)-acetic acid-(2,2-diethoxy-ethylamide) 
• 288395-89-1 N-[(4-benzyloxy-phenyl)-acetyl]-glycine 
• 61172-72-3 4-(4-Benzyloxy-phenyl)-2-tert-butoxycarbonylamino-3-oxo-butyric acid methyl ester 
• 58609-24-8 2-(4-(benzyloxy)phenyl)-N-(p-tolyl)acetamide 
• 58609-22-6 2-(4-Benzyloxy-phenyl)-N-(5-chloro-2-methoxy-phenyl)-acetamide 
• 142272-40-0 Octyl-4-benzyloxyphenyl acetate 
• 151562-44-6 1,8-Dihydroxy-10-[1-oxo-2-(4-phenylmethoxyphenyl)ethyl]-9(10H)-anthracenone 
• 23428-48-0 N-(3,4-dibenzyloxyphenethyl)-4-benzyloxyphenylacetamide 
• 83532-52-9 2-(3-Benzyloxy-4-methoxyphenacyl)-N-(4-benzyloxyphenylacetyl)-pyrrolidine 
• 79624-53-6 N-(4,5-bisbenzyloxy-3-methoxyphenethyl)-2-(4-benzyloxyphenyl)acetamide 
• 181268-39-3 4-{[2-(4-Benzyloxy-phenyl)-acetyl]-phenethyl-amino}-butyric acid ethyl ester 

Relevant academic research and scientific papers

Synthetic studies toward melotenine A

Attempts to the construction of B/C ring and E ring in melotenine A are described. Based on para-dienone chemistry, a tactical application of tandem aminolysis/aza-Michael addition reaction was made to access highly functionalized building blocks with the

Structure-supercooling property relationship of phenylethyl phenylacetate derivatives and analogue

In this paper, three new compounds were synthesized by introduction of benzyloxy group to phenylethyl phenylacetate (PPA) and shorting the flexible ester linker. NMR spectra and mass spectra are achieved to confirm the structure of the compounds. The solid-liquid and liquid-solid phase change behaviors of PPA and these three compounds were explored by direct observation and differential scanning calorimetry (DSC) measurements. It was found that all four compounds would form supercooled liquids during a heating-cooling cycle. The supercooling degree is as large as 44 °C or above. The effects of benzyloxy group and the flexible linker on the phase transition processes as well as the supercooling degrees were discussed in detail with the computational optimized geometry of isolated molecules. It was revealed that the dihedral angles between adjacent phenyl rings play a significant role in tuning their phase transition temperatures. This work also discovers the high enthalpies of PPA derivatives and analogues in both solid-liquid and liquid-solid phase transition processes, making them great potentials for the thermal energy control of appropriate working temperature regions.

PdII-Catalyzed methoxylation of C(sp3)-H bonds adjacent to benzoxazoles and benzothiazoles

The Pd(OAc)2/PhI(OAc)2 catalyst system promotes the highly regioselective dehydrogenative methoxylation of a C(sp3)-H bond adjacent to benzoxazole and benzothiazole rings. The title transformation constitutes the first example of a Pd-catalyzed C(sp3)-H activating methoxylation at the proximal-selective α-position with regard to a directing auxiliary and provides expedient access to an important class of azole-decorated methyl ethers (up to 90% isolated yield). The synthetic practicality of the methodology was demonstrated by achieving α-methoxyacetic acids via the elimination of the benzoxazole auxiliaries and by obtaining the precursor of an O-methylated Breslow intermediate.

POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE

The invention provides compositions and methods for the treatment or prevention of pain. Compositions provided are resistant to overdose and abuse. Compositions provided comprise two or more different molecules, where each molecule comprises at least one GI enzyme-labile opioid agonist releasing subunit comprising an opioid agonist that is covalently linked to at least one GI enzyme inhibitor subunit.

Design, synthesis, and biological evaluation of oxazolidone derivatives as highly potent N-acylethanolamine acid amidase (NAAA) inhibitors

N-Acylethanolamine-hydrolyzing acid amidase (NAAA) is a lysosomal enzyme that catalyzes the hydrolysis of endogenous fatty acid ethanolamides (FAEs), such as N-palmitoylethanolamide (PEA). PEA exhibits anti-inflammatory and analgesic activities by engaging peroxisome proliferator-activated receptor α (PPAR-α). Preventing PEA degradation by inhibition of NAAA has been proposed as a novel strategy for the treatment of inflammation and pain. In the present study, we reported the discovery of the oxazolidone derivative as a novel scaffold for NAAA inhibitors, and studied the structure-activity relationship (SAR) by modification of the side chain and terminal lipophilic substituents. The results showed that the link chain length of C5, straight and saturated linkages were the preferred shape patterns for NAAA inhibition. Several nanomolar NAAA inhibitors were described, including 2f, 3h, 3i and 3j with IC50 values of 270 nM, 150 nM, 100 nM and 190 nM, respectively. Enzymatic degradation studies suggested that 2f inhibited NAAA in a selective, noncompetitive and reversible pattern. Moreover, 2f showed high anti-inflammatory and analgesic activities after systemic and oral administration.

Asymmetric total synthesis of Apocynaceae hydrocarbazole alkaloids (+)-deethylibophyllidine and (+)-limaspermidine

An unprecedented asymmetric catalytic tandem aminolysis/aza-Michael addition reaction of spirocyclic para-dienoneimides has been designed and developed through organocatalytic enantioselective desymmetrization. A unified strategy based on this key tandem

Designing new analogs for streamlining the structure of cytotoxic lamellarin natural products

Despite the therapeutic potential of marine-derived lamellarin natural products, their preclinical development has been hampered by their lipophilic nature, causing very poor aqueous solubility. In order to develop more drug-like analogs, their structure was streamlined in this study from both the cytotoxic activity and lipophilicity standpoints. First, a modified total synthetic route was successfully devised to construct a library of 59 systematically designed lamellarin analogs, which were then subjected to cytotoxicity and log P determinations. Along with the 25 first-generation lamellarins previously synthesized in our laboratory, the structure-activity and structure-lipophilicity relationships were extensively evaluated. Our results clearly indicated the additional structural requirements around the lamellarin skeleton which, when combined with those reported previously, can provide invaluable guidance for further modifications to increase the aqueous solubility of these compounds.

Synthesis and in vitro antitumor activity of asperphenamate derivatives as autophagy inducer

In an effort to improve the aqueous solubility and the antitumor activity of natural product asperphenamate, we have designed and synthesized three series of asperphenamate derivatives, including series I (simplifying molecular skeleton series), series II (introducing a hydroxyl group to A-phenyl ring series) and series III (disrupting molecular planarity series). All derivatives have displayed a significantly increased solubility compared with asperphenamate. Their growth inhibitory activities in vitro were screened by the standard MTT method in MCF-7, HeLa, and BEL-7402 cell lines. With the exception of the derivatives in series I, most of derivatives in series II and series III showed growth inhibitory activity. Among all derivatives, IM23b in series III showed the greatest potency in human breast cancer MCF-7 cells. The cellular potency of IM23b was approximately 1.5-fold more potent than that of cisplatin. The mechanism of cell death induced by IM23b in human breast cancer MCF-7 cells was further investigated. We concluded that the cell death was induced by autophagy instead of apoptosis or cell cycle arrest.

Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents

The synthesis and antiproliferative activity of a new series of rigid analogues of combretastatin A-4 are described which contain the 1,4-diaryl-2-azetidinone (β-lactam) ring system in place of the usual ethylene bridge present in the natural combretastatin stilbene products. These novel compounds are also substituted at position 3 of the β-lactam ring with an aryl ring. A number of analogues showed potent nanomolar activity in human MCF-7 and MDA-MB-231 breast cancer cell lines, displayed in vitro inhibition of tubulin polymerization, and did not cause significant cytotoxicity in normal murine breast epithelial cells. 4-(4-Methoxyaryl)-substituted compound 32, 4-(3-hydroxy-4-methoxyaryl)-substituted compounds 35 and 41, and the 3-(4-aminoaryl)-substituted compounds 46 and 47 displayed the most potent antiproliferative activity of the series. β-Lactam 41 in particular showed subnanomolar activity in MCF-7 breast cancer cells (IC50 = 0.8 nM) together with significant in vitro inhibition of tubulin polymerization and has been selected for further biochemical assessment. These novel β-lactam compounds are identified as potentially useful scaffolds for the further development of antitumor agents that target tubulin.

Design, Synthesis, and Biological Evaluation of New 8-Heterocyclic Xanthine Derivatives as Highly Potent and Selective Human A2B Adenosine Receptor Antagonists

Here we report the synthesis of 8-heterocycle-substituted xanthines as potent and selective A2B adenosine receptor antagonists. The structure-activity relationships (SAR) of the xanthines synthesized in binding to recombinant human A2B adenosine receptors (ARs) in HEK-293 cells (HEK-A2B) and at other AR subtypes were explored. The synthesized compounds showed A2B adenosine receptor affinity in the nanomolar range and good levels of selectivity evaluated in radioligand binding assays at human (h) A1, A2A, A2B, and A3 ARs. We introduced several heterocycles, such as pyrazole, isoxazole, pyridine, and pyridazine, at the 8-position of the xanthine nucleus and we have also investigated different spacers (substituted acetamide, oxyacetamide, and urea moieties) on the heterocycle introduced. Various groups at the 3- and 4-positions of phenylacetamide moiety were studied. This study allowed us to identify the derivatives 2-(3,4-dimethoxyphenyl)-N-[5-(2,6-dioxo-1,3-dipropyl-2,3,6, 7-tetrahydro-1H-purin8-yl)-1-methyl-1H-pyrazol-3-yl] acetamide (29b, MRE2028F20) [Ki(hA2B) = 38 nM, Ki(hA1,hA 2A,-hA3) >1000 nM], N-benzo[1,3]dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6, 7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy] acetamide (62b, MRE2029F20) [Ki(hA2B) = 5.5 nM, Ki(hA 1,hA2A,hA3) > 1000 nM], and N-(3,4-dimethoxyphenyl)-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6, 7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy] acetamide (72b, MRE2030F20) [Ki(hA2B = 12 nM, Ki(hA 1,hA2A, hA3) > 1000 nM], which showed high affinity at the A2B receptor subtype and very good selectivity vs the other ARs. Substitution of the acetamide with an urea moiety afforded bioisosteric xanthines with good affinity and selectivity comparable to the acetamide derivatives. Substitution at the para-position of a 4-benzyloxy group of the phenylacetamido chain enhanced affinity at the A2B receptor [compound 30b (Ki(hA2B) = 13 nM) vs compound 21b (K i(hA2B = 56 nM)] but did not favor selectivity. The derivatives with higher affinity at human A2B AR proved to be antagonists, in the cyclic AMP assay, capable of inhibiting the stimulatory effect of NECA (100 nM) with IC50 values in the nanomolar range, a trend similar to that observed in the binding assay (62b, IC50 = 38 nM; 72b, IC50 = 46 nM). In conclusion, the 8-pyrazolo-1,3-dipropyl-1H-purine-2,6-dione derivatives described herein represent a new family of selective antagonists for the adenosine A 2B receptor.